medigraphic.com
Colegio de Medicina Interna de México.

2021, Número 5

<< Anterior Siguiente >>

Med Int Mex 2021; 37 (5)


Azilsartán, el inhibidor más afín y fiel al receptor AT1 de angiotensina II. Revisión de la bibliografía y reporte de la experiencia con azilsartán y azilsartán-clortalidona en un centro de cardiología preventiva

Morales-Villegas EC, Alcocer-Díaz-Barreiro LA, Moreno-Virgen G

Idioma: Español
Referencias bibliográficas: 32
Paginas: 781-799
Archivo PDF: 337.97 Kb.


RESUMEN

Este artículo tiene como propósito resumir la evidencia de una excelente opción terapéutica para el control de la hipertensión arterial, se hace una revisión de la estructura, los efectos in vitro y los efectos experimentales de azilsartán (AZL). Esta información proporciona el soporte básico para explicar los excelentes resultados clínicos de azilsartán y azilsartán más clortalidona (AZL-CLD) tanto en la fase III experimental aquí revisada, como en la vida real en nuestro Centro, del que se reporta en forma descriptiva la experiencia con azilsartán y AZL-CLD.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/ AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. J Am Coll Cardiol 2017, doi: 10.1016/j.jacc.2017.11.006.

  2. Guía ESC-ESH 2018. DOI: 10.1016/j.recesp.2018.12.005.

  3. Ojima M, Igata H, Tanaka M, Sakamoto H, et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, Azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 2011; 336: 801-808. doi: 10.1124/jpet.110.176636.

  4. Kusumoto K, Igata H, Ojima M, et al. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models. Eur J Pharmacol 2011; 669: 84-93. doi: 10.1016/j.ejphar.2011.07.014.

  5. Iwai M, Imura Y, Chen R, Horiuchi M. TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. Am J Hypertens 2007; 20: 579-586. doi: 10.1016 / j.amjhyper.2006.12.010.

  6. Zhao M, Li Y, Wang J, Ebihara K, et al. Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletzky rats. Diabetes Obes Metab 2011; 13: published online 12 July 2011. Doi.org/10.1111/j.1463- 1326.2011.01471.x

  7. Kajiya T, Ho C, Wang J, Vilardi R, Kurtz TW. Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker. J Hypertens 2011; 29: 2476-2483. doi: 10.1097/HJH.0b013e32834c46fd.

  8. Naruse M, Koike Y, Kamei N, Sakamoto R, Yambe Y, Arimitsu M. Effects of azilsartan compared with telmisartan on insulin resistance in patients with essential hypertension and type 2 diabetes mellitus: an open-label randomized clinical trial. PLoS One 2019; 14 (4): e0214727. doi: 10.1371/ journal.pone.0214727.

  9. White WB, Weber MA, Sica D, Bakris GL, et al. Effects of the angiotensin receptor blocker Azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011; 57: 413-420. doi: 10.1161/HYPERTENSIONAHA. 110.163402.

  10. Sica D, White WB, Weber MA, Bakris GL, et al. Comparison of a novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich) 2011; 13: 467- 472. doi: 10.1111/j.1751-7176.2011.00482.x.

  11. Bakris GL, Sica D, Weber M, White W, et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich) 2011; 13: 81-88. doi: 10.1111/j.1751-7176.2010.00425.x.

  12. Rakugi H, Enya K, Sugiura K, Ikeda Y. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. Hypertens Res 2012; 35: 552-558. doi: 10.1038/hr.2012.8.

  13. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until March 2003. J Hypertens 2003; 21: 1055-1076. doi: 10.1097/00004872-200306000-00002.

  14. Carter BL, Ernst M, Cohen JD. Hydrochlorothiazide versus chlortalidone: Evidence supporting their interchangeability. Hypertension 2004; 43: 4-9. doi: 10.1161/01. HYP.0000103632.19915.0E.

  15. Khosla N, Chua DY, Elliot WJ, Bakris GL. Are chlortalidone and hydrochlorothiazide equivalent blood-pressurelowering medications? J Clin Hypertens 2005; 7: 354-356. doi: 10.1111/j.1524-6175.2005.04451.x.

  16. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlortalidone on ambulatory and office blood pressure. Hypertension 2006; 46: 352-358. doi: 10.1161/01. HYP.0000203309.07140.d3.

  17. Sica DA. Chlortalidone: Has it always been the best thiazide-type diuretic? Hypertension 2006; 47: 321-322. doi: 10.1161/01.HYP.0000203147.75714.ba.

  18. Flack JM, Sica DA, Nesbitt S. Chlortalidone versus hydrochlorothiazide as the preferred diuretic: Is there a verdict yet? Hypertension 2011; 57: 665-666. doi: 10.1161/ HYPERTENSIONAHA.110.164566.

  19. Kaplan N. Chlortalidone versus hydrochlorothiazide: A tale of tortoises and a hare. Hypertension 2011; 58: 994-995. doi: 10.1161/HYPERTENSIONAHA.111.183525.

  20. Peterzan MA, Hardy R, Chaturvedi N, Hughes A. Metaanalysis of dose-response relationships for hydrochlorothiazide, chlortalidone, and Bendroflumethiazide on blood pressure, serum potassium and urate. Hypertension 2012; 59: 1104-1109. doi: 10.1161/HYPERTENSIONAHA. 111.190637.

  21. Weir MR, Agarwal R. Thiazide and thiazide-like diuretics: Perspectives on individualization of drug and dose based on therapeutic index. Hypertension 2012; 59: 1089-1090. doi: 10.1161/HYPERTENSIONAHA.112.192153.

  22. Ernst ME, Neaton JD, Grimm RH, Collins G, et al. Long-term effects of chlortalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the Multiple Risk Factor Intervention Trial. Hypertension 2011; 58: 1001-1007. doi: 10.1161/HYPERTENSIONAHA.111.181248.

  23. MRFIT Research Group. Mortality after 10 ½ years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation 1990; 82: 1616-1628. doi: 10.1161/01.cir.82.5.1616.

  24. Dorsh MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlortalidone reduces cardiovascular events compared with hydrochlorothiazide: A retrospective cohort analysis. Hypertension 2011; 57: 689-694. doi: 10.1161/HYPERTENSIONAHA. 110.161505.

  25. Roush GC, Holford TR, Guddati AK. Chlortalidone compared with hydrochlorothiazide in reducing cardiovascular events: Systematic review and network meta-analysis. Hypertension 2012; 59: 1110-1117. doi: 10.1161/HYPERTENSIONAHA. 112.191106.

  26. Jennings GLR. Recent clinical trials of hypertension management. Hypertension 2013; 62: 3-7. doi: 10.1161/ HYPERTENSIONAHA.113.00863.

  27. Engberick RHGO, Frenkel WJ, van den Bogaard B, Brewster LM, et al. Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: Systematic review and meta-analysis. Hypertension 2015; 65: 1033-1040. doi: 10.1161/HYPERTENSIONAHA.114.05122.

  28. Sica D, Bakris GL, White WB, Weber M, et al. Blood pressure lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlortalidone: A factorial study. J Clin Hypertens (Greenwich) 2012; 14: 284-292. doi: 10.1111/j.1751-7176.2012.00616.x.

  29. Bakris GL, Sica D, White WB, Cushman WC, et al. Antihypertensive efficacy with hydrochlorothiazide vs chlortalidone combined with azilsartan medoxomil. Am J Med 2012; 125: 1129.e1-1229.e10. doi: 10.1016/j.amjmed.2012.05.023.

  30. Cushman WC, Bakris GL, White WB, Weber MA, et al. Azilsartan medoxomil plus chlortalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension 2012; 60: 310-318. doi: 10.1161/HYPERTENSIONAHA.111.188284.

  31. Takagi H, Misuno Y, Niwa M, Goto SN, Umemoto T. A meta-analysis of randomized controlled trials of azilsartan therapy for blood pressure reduction. Hypertens Res 2014; 37: 432-437. doi: 10.1038/hr.2013.142.

  32. Bakris GL, Zhao L, Kupfer S, Hisada M, et al. Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorotiazide in chronic kidney disease. J Clin Hypertens 2018: 1-9. doi: 10.1111/jch.13230.




2020     |     www.medigraphic.com